

Home Antibody

Target

Orga

Latest Update: Jun 24, 2022

## Arthritis, rheumatoid

Category: Immune System|Musculoskeletal

Antibody Therapies: 112

Antibody Name 🔷	Targets <b>♦</b>	Organization \$	Status \$		
608 3SBio	IL-17	3SBio	Phase 2		
adalimumab	ΤΝΕα	CAT (AstraZeneca) AstraZeneca Abbvie Eisai	Approved		
adalimumab biosimilar, Zydus Cadila /Glenm ark	ΤΝΕα	Zydus Healthcare Glenmark Pharmaceuticals	Approved		
adalimumab biosimilar, Torrent/Reliance Life Sciences	ΤΝΕα	Reliance Torrent Pharma	Approved		
adalimumab biosimilar, Amgen	ΤΝΕα	Amgen	Approved		
adalimumab biosimilar, Merck & Co./Samsu ng Bioepis	TNFα	Samsung Bioepis Merck (MSD)	Approved		
adalimumab biosimilar, Boehringer Ingelhei m	ΤΝΕα	Boehringer Ingelheim	Approved		
adalimumab biosimilar, Hetero Drugs	ΤΝΕα	Hetero Drugs	Approved		
adalimumab biosimilar, Sandoz (Novartis)	ΤΝΕα	Novartis	Approved		
adalimumab biosimilar, Bio-Thera Solutions	ΤΝΕα	Bio-Thera	Approved		
adalimumab biosimilar, Pfizer	ΤΝΕα	Pfizer	Approved		
adalimumab biosimilar, Fujifilm Kyowa Kirin Biologics	ΤΝΕα	Fujifilm Kyowa Kirin	Approved		
adalimumab biosimilar, Innovent Biologics	ΤΝΕα	Innovent	Approved		
adalimumab biosimilar, Celltrion	ΤΝΕα	Celltrion	Approved		
adalimumab biosimilar, Fresenius Kabi	ΤΝΕα	Fresenius Kabi	Approved		
adalimumab biosimilar, LG Life Sciences	ΤΝΕα	LG Life Sciences (LG Chem)	Approved		
adalimumab biosimilar, Coherus	ΤΝΕα	Coherus	Approved		
adalimumab biosimilar, Zhejiang Hisun Phar maceutical	ΤΝΕα	Zhejiang Hisun	Phase 3		



Home Antibody Target Orga Biocon adalimumab biosimilar, Biocon TNFα Phase 3 Mylan adalimumab biosimilar, Cinnagen TNFα CinnaGen Phase 3 Huaota adalimumab biosimilar, Zhejiang Huahai  $\mathsf{TNF}\alpha$ Phase 3 Huahai adalimumab biosimilar, BIOCND/Genor Biop **BIOCND** TNFα Phase 1 harma Genor (Walvax Biotechnology) adalimumab biosimilar, Synermore Biologics Phase 1 TNFα Synermore DM Bio adalimumab biosimilar, DMBio TNFα Phase 1 adalimumab biosimilar, Tanvex Biopharma  $\mathsf{TNF}\alpha$ Tanvex Preclinical Arthrofoon TNFα Materia Medica Approved Adalimumab biosimilar TNFα Shanghai Henlius Approved **BUCHANG** Adalimumab biosimilar - Buchang  $\mathsf{TNF}\alpha$ Phase 3 ABBV-3373 TNFα Abbvie Phase 2 BI 655064 CD40 Boehringer Ingelheim Phase 2 Biogen BAFF-R Briobacept Phase 2 Genentech (Roche) IL-17 BCD-121 Biocad Phase 1  $\mathsf{TNF}\alpha$ Astellas Celltech (UCB) certolizumab pegol TNFα Dermira Approved UCB Xoma canakinumab IL-1β Novartis Approved Janssen-Cilag CNTO-6785 JL-17 Phase 2 MorphoSys IL-17 COVA322 Covagen Phase 2 TNFα Amgen GSK RANKL denosumab AstraZeneca Approved Dr. Reddy's Chong Kun Dang Viela Bio (Horizon Pharma) CD40L Dazodalibep Phase 3

Total 113	40/page	~	<	1	2	3	>	Go to	1

Medimmune (AstraZeneca)

Copyright 2021 - 2022 UMABS All Rights Reserved.

